Multiple myeloma (MM) is a plasma cell disorder that is on the rise throughout the world,
especially in the US, Australia, and Western Europe. In the US, MM accounts for almost 2 …

Multiple myeloma (MM) is the second‐ranking malignancy in hematological tumors. The
pathogenesis of MM is complex with high heterogeneity, and the development of the …

Background: Carfilzomib, an effective proteasome inhibitor agent for the therapy of relapsed
and refractory multiple myeloma, has been related to a significant number of cardiovascular …

Although venous thromboembolism (VTE) is an important treatment and disease-related
complication in myeloma, a validated risk prediction model including disease-specific …

Importance Cancer treatment can result in burdensome toxic effects that profoundly affect
patient quality of life. In seeking to emphasize the efficacy of tested treatments, clinical trial …

Multiple myeloma (MM) is a hematologic neoplasm of plasma cells that is currently deemed
incurable. Despite the introduction of novel immunomodulators and proteasome inhibitors …

Multiple myeloma (MM) is a malignant clonal plasma cell disorder in the bone marrow and is
the second-most common hematologic malignancy in adults. Although patients with MM …

The overall survival in patients with transplantation-eligible multiple myeloma has tripled
over the past 2 decades, leading to a growing population of myeloma survivors. However …

Multiple myeloma (MM) is the second most prevalent hematological malignancy. Current
MM treatment strategies are hampered by systemic toxicity and suboptimal therapeutic …

Multiple myeloma (MM) is an incurable cancer that is characterized by malignant plasma cell
proliferation. Approximately 10% of all blood cancers are MM, and there is no standard …